Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ALX Oncology Inc.
The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of ALX148 in combination with azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination with azacitidine compared to azacitidine alone for patients with previously untreated higher risk MDS.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Phase 1: Diagnosis of higher risk MDS that is either previously untreated or relapsed/refractory.
Phase 2: Diagnosis of higher risk MDS that is previously untreated.
Adequate renal and liver function.
Age ≥18 years.
Adequate performance status.
You may not be if
Previous allogeneic hematopoietic stem cell transplant (allo-HSCT) for MDS or AML.
Prior treatment with any anti-CD47 or anti-SIRPα (signal regulatory protein alpha) agent.
Known active viral infections, including hepatitis B and C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
Clareo Health | A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
